ipharmacenter Consulting services

On September 30, Novartis announced that the U.S. Food and Drug Administration’s approval of Rhapsido (remibrutinib) for chronic spontaneous urticaria (CSU). This innovative therapy is the first oral, targeted BTK inhibitor designed exclusively for CSU- a condition marked by unpredictable outbreaks of hives and severe itching, adversely affecting millions

AbbVie announced positive topline results from its second Phase 3 UP-AA trial for the alopecia areata treatment, Rinvoq (upadacitinib). The study showed that both the 15 mg and 30 mg doses of the drug met the primary endpoint, leading to significant scalp hair regrowth in a large percentage of patients after 24 weeks. A key finding from the trial was the significant difference in outcomes compared to placebo. At week 24, 45.2% of patients on the 15 mg dose and 55.0% of those